Siemens Healthcare Diagnostics International Allergy Conference

131 Pages·2009·2.85 MB·English

S
i
e
m
e
n
s

I
n
t
e
r
n
a
t
i
o
n
a
l

A
l
l
e
r
g
y

C
o
n
f
e
r
e
n
c
Siemens Healthcare Diagnostics, the leading e

clinical diagnostics company, is committed | J
to providing clinicians with the vital information u
n
they need for the accurate diagnosis, treatment e
and monitoring of patients. Our comprehensive 12
portfolio of performance-driven systems, , 2
unmatched menu offering and IT solutions, 0
0
in conjunction with highly responsive service, 8
iesn dheasnigcen eodp etora sttiroenaaml elifnfiec wieonrckyfl aonwd, s upport | Je
a
improved patient care. n-C
h
a
rle
s
IMMULITE, 3gAllergy, and all associated marks are C
trademarks of Siemens Healthcare Diagnostics Inc. lou
e
All other trademarks and brands are the property t
of their respective owners.
Product availability may vary from country
to country and is subject to varying
regulatory requirements. Please contact
your local representative for availability.
Siemens Global Headquarters Global Siemens Global Division
Healthcare Headquarters
Siemens AG Siemens Healthcare Diagnostics Inc. Siemens Healthcare Diagnostics
Wittelsbacherplatz 2 Siemens AG 1717 Deerfield Road
80333 Muenchen Healthcare Sector Deerfield, IL 60015-0778 International Allergy Conference
Germany Henkestrasse 127 USA
91052 Erlangen www.siemens.com/diagnostics Barcelona, Spain
Germany
June 12, 2008
Telephone: [phone] - 0
www.siemens.com/healthcare
Jean-Charles Clouet, Editor
Answers for life.
www.siemens.com/diagnostics
Order No. A91DX-0701505-XC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc.
Proceedings of the
Siemens Healthcare Diagnostics
International Allergy Conference
Barcelona, Spain
June 12, 2008
Jean-Charles Clouet, Editor

Contents
Preface vii
Acknowledgments ix
Part 1: Lecture Summaries
1.1 In Vitro Allergy Diagnostics: New Guidelines from the Clinical 2
and Laboratory Standards Institute (CLSI)
R. Hamilton (Division of Allergy and Clinical Immunology,
Johns Hopkins University School of Medicine, Baltimore, MD, US)
1.2 Diagnosis of Cow’s Milk Allergy: Are Low Levels of Specific IgE Significant? 8
A. M. Plaza (Sant Joan de Déu Hospital, Barcelona, Spain)
1.3 Integration of In Vitro Allergy Testing into Laboratory Automation: A Lean Approach 12
J. Geijer (Unilabs, St Göran Hospital, Stockholm, Sweden)
1.4 Future Diagnostic Tools for Better Practice and Interpretation in 16
Allergic Diseases: From New In Vitro Markers to IT Integrated Solutions
A. Mari (CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
1.5 Chimeric Antibodies in Allergy Testing: Description of Potential Applications 26
T. Grunwald (PLS-Design GmbH, Hamburg, Germany)
1.6 Future Clinical Applications of Molecular Allergens for Specific IgE 38
and IgG/IgG4 Testing
M. Ollert (Technische Universität München [TUM], Munich, Germany)
1.7 Allergo-oncology: Introduction of a Novel Concept 46
E. Jensen-Jarolim (Department of Pathophysiology,
Medical University, Vienna, Austria)
1.8 Siemens Healthcare Diagnostics’ New Developments in Allergy 52
D. Hovanec-Burns (Allergy Diagnostics, Siemens Healthcare Diagnostics,
Los Angeles, CA, US)
Part 2: Scientific Posters
2.1 Cross-reactive Carbohydrate Determinant (CCD) from Bromelain: 63
A New Allergy Marker (MUXF Glycopeptide) for Specific IgE Detection
U. Banik1, K. Huynh1, W. X. Gan1, R. A. Evangelista1, M. Lopez1,
K. Jaggi1, D. Davoudzadeh1, P. Palazzo2, M. L. Bernardi2, A. Mari2,
D. Hovanec-Burns1 (1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.2 Native Art v 1: Evaluation of a Molecular Allergen for Mugwort Pollen Allergy 69
M. Sen1, K. Huynh1, R. Evangelista1, K. Jaggi1, D. Davoudzadeh1, P. Palazzo2,
D. Zennaro2, A. Mari2, D. Hovanec-Burns1, U. Banik1
(1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
iii
2.3 Evaluation of Native Birch Molecular Allergen nBet v 1: Major Allergen 73
for Birch Pollen Allergy Diagnosis
M. Ordonez1, K. Huynh1, R. Rouhani1, R. Evangelista1, K. Jaggi1, D. Hovanec-Burns1,
D. Davoudzadeh1, R. Ferrara2, L. Pirrotta2, A. Mari2, U. Banik1
(1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.4 Native Ole e 1: Evaluation of a Molecular Allergen for Olive Pollen Allergy 77
M. Sen1, K. Huynh1, R. Evangelista1, K. Jaggi1, D. Davoudzadeh1, D. Zennaro2,
M. Giani2, A. Mari2, D. Hovanec-Burns1, U. Banik1 (1Siemens Healthcare Diagnostics,
Los Angeles, CA, US; 2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.5 Evaluation of Native Major Peach Allergen nPru p 3: A Lipid Transfer Protein 81
for Allergy Diagnosis
M. J. Marañón1, K. Huynh1, M. Poladian1, A. Drummond1, M. Lopez1, K. Jaggi1,
D. Davoudzadeh1, A. Zaffiro2, D. Quaratino2, A. Mari2, D. Hovanec-Burns1, U. Banik1
(1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.6 Evaluation of Recombinant PR-10 Allergens rMal d 1 and rPru av 1: Diagnostic Tools 87
for Allergen Cross-reactivity
M. J. Marañón1, K. Huynh1, M. Poladian1, R. Evangelista1, A. Drummond1, M. Lopez1,
K. Jaggi1, D. Davoudzadeh1, E. Scala2, M. L. Bernardi2, A. Mari2, D. Hovanec-Burns1,
U. Banik1 (1Siemens Healthcare Diagnostics, Los Angeles, CA, US; 2CACeS, IDI-IRCCS,
Allergy Data Laboratories sc, Latina, Rome, Italy)
2.7 Development of Recombinant Cherry Profilin rPru av 4 Allergen: An Emerging Tool 93
for Investigating Cross-reactivity
U. Banik1, M. J. Marañón1, M. Poladian1, A. Drummond1, M. Lopez1, K. Jaggi1,
D. Davoudzadeh1, M. Giani2, R. Fantini2, A. Mari2, D. Hovanec-Burns1
(1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.8 Native Cat and Dog Allergenic Molecules nFel d 1 and nCan f 1: New Tools for 99
Component-Resolved Allergy Diagnosis
M. J. Marañón1, U. Banik1, S. Maldonado1, M. Lopez1, K. Jaggi1, D. Quaratino2,
D. Zennaro2, A. Mari2, D. Hovanec-Burns1, D. Davoudzadeh1
(1Siemens Healthcare Diagnostics, Los Angeles, CA, US;
2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.9 Native Mite Allergenic Molecules nDer p 1, nDer p 2, nDer f 1 and nDer f 2: 105
Novel Tools for Mite Component-Resolved Allergy Diagnosis
U. Banik1, M. J. Marañón1, A. Achiles1, M. Lopez1, K. Jaggi1, R. Ferrara2, D. Pomponi2,
A. Mari2, D. Davoudzadeh1, D. Hovanec-Burns1 (1Siemens Healthcare Diagnostics,
Los Angeles, CA, US; 2CACeS, IDI-IRCCS, Allergy Data Laboratories sc, Latina, Rome, Italy)
2.10 Development and Analytical Performance of the IMMULITE® 2000 109
Allergen-Specific IgG Assay
T. Chuang, M. Walker, R. Rouhani, A. Hoang, D. Hovanec-Burns
(Siemens Healthcare Diagnostics, Los Angeles, CA, US)
2.11 Allergen-Specific IgG4 Detection on the IMMULITE® 2000 System 115
T. Chuang, S. Maldonado, H. Kubota, D. Hovanec-Burns
(Siemens Healthcare Diagnostics, Los Angeles, CA, US)
iv

Preface
Mr. Jean-Charles Clouet
Director Marketing, Assays
Europe, Middle East, Africa
Siemens Healthcare Diagnostics
In vitro measurements of allergen-specific IgE Siemens sponsored an International Allergy
(sIgE) are well-established tests used by most Conference on June 12, 2008, in Barcelona,
laboratories worldwide for the diagnosis of Spain. It was my privilege then to welcome the
IgE-mediated allergic diseases. In recent years, conference participants, and it is a pleasure for
however, important innovations have tremen- me now, on behalf of the Company, to offer
dously modified the allergy testing paradigm, these proceedings, which include summaries
and other advances are appearing on of the scientific lectures and posters presented
the horizon. during the conference.
From new detection technologies like chemilu- Through this proceedings volume, I would also
minescence emerged highly sensitive methods like to extend to you, the reader, an invita-
with the ability to detect sIgE at concentra- tion to learn more about 3gAllergy tests; to
tions far below historical analytical limits. The become better acquainted with new tools such
development of fully automated laboratory as molecular allergens, anti-CCD markers, and
instruments allowing centralization of allergy chimeric IgE antibodies that are becoming avail-
tests with other immunoassays (such as able for diagnostic or research purposes; and
those for hormones, tumor markers, and even to discover that allergy mechanisms are
infectious diseases) was another critical being investigated as a possible weapon to help
milestone towards an optimized integration combat cancer!
of allergy testing in the laboratory workflow.
It is my hope that you will benefit from the
Siemens Healthcare Diagnostics has contrib- lecture summaries and posters included in
uted actively to all of these innovations. these proceedings. I wish you good reading,
With the introduction of 3gAllergy™ tests on and I hope that we can continue to take allergy
IMMULITE® 2000 immunoassay system, allergy diagnostics to the next level. Together.
testing could be consolidated for the first
time alongside routine immunoassays.Today,
IMMULITE 2000 and IMMULITE® 2500 remain
the only platforms that provide workstation
consolidation and random access testing for
allergy and more than 90 other immunoassays.
vii

Acknowledgments
Siemens Healthcare Diagnostics is
indebted to Prof. Markus Ollert of the
Dermatology and Allergology Department of
the Technische Universität München for having
been a wonderful conference chairman, moder-
ating the introductory and concluding sessions
of the day. We also want to thank all the
speakers for the excellence of their presenta-
tions. Finally, we are very grateful to the many
participants from all over Europe who attended
this event.
A word of thanks also goes to Mike Geier
and Connie Colin of Clinical Marketing
and Scientific Publications for editing the
manuscript, and to Michelle Muse of
Eagle Eye Graphics for graphic design.
ix